Iparomlimab and Tuvonralimab in Combination with Trastuzumab Rezetecan for the Treatment of HER2-low Advanced Breast Cancer: A Single-arm, Multicenter, Phase II Clinical Study

Authors
Category Primary study
Registry of TrialsChinese Clinical Trial Register
Year 2026
This article has no abstract
Epistemonikos ID: 2db0ca9bafc3f5dad3982eb4fa0e2ff7a9ecbd81
First added on: Oct 10, 2026